IT is generally recognised that one of the most lethal aspects of malignant neoplasia is the formation of metastases (Foulds, 1969) . As a result, a great deal of information has been presented on the mechanism of invasion, lodgement and establishment of metastases (Baserga, Kisieleski and Halvorsen, 1960; Carr, Norris and McGinty, 1975; Saidel, Liotta and Kleinerman, 1976) . It has been suggested that metastasis results from the selection of tumour cells, and it may be that this selective lodgement gives rise to a clone of cells which behave differently from those of the primary tumour (Trope, 1975) . Obviously, any differences in behaviour between the primary tumour and its metastases is relevant to therapy. The Walker 256 carcinoma is widely used in pharmacological studies, but is rarely the model for metastatic growth. It was, therefore, the aim of the present work to quantify cellular proliferation in the primary, solid Walker tumour relative to metastases, as well as to determine the influence of lodgement site on the development of metastases. were corrected to numbers of whole cells, using the Floderus correction formula (Marrable, 1962) .
RESULTS
Following the initial establishment, from 0 to 3 days, the growth of the s.c. tumour was exponential up to 8 days (Fig. 1) With the exception of the thymus, where isolated tumour cells were occasionally observed beneath the capsule, metastases were not found in any other tissue, and were notably absent from liver, kidney and spleen. Fig. 2 shows the overall 4h-accumulated mitotic count of the s.c. solid tumour from the time of growth initiation at 2 days until death occurred at 9 days. As the tumour became established in the host and underwent the initial growth phase between 2 and 4 days, a 2-fold increase in cellular proliferation was observed. Thereafter, the 4h-accumulated MI remained constant until the time of death. This corresponded with the period when maximum growth rate was observed.
Insufficient clusters of tumour cells were present in the lungs until 6 days, and in the lymph nodes until 9 days after injection, to warrant counting. At 6 days the 4h-accumulated mitotic count in lung metastases was significantly higher than that observed in the solid s.c. tumour (Fig. 2) . A further increase in lung-tumour cellular proliferation was observed at 8 days, but on the 9th day after injection the 4h-accumulated MI fell dramatically.
The 4h-accumulated MI in lymph-node metastases, at 9 days, was significantly higher than that of either the primary tumour or the lung metastases at this stage (Fig. 2) . However, the rate of cellular proliferation was comparable in the lymphnode metastases at 9 days and the lung metastases at 8 days, when the peak accumulated MI was observed.
When metastatic cells were counted in the lungs, the microscope fields were categorised according to the presence of lung tissue interspersed with tumour cells, the peripheral 1 20um of the main tumour mass or the central tumour mass.
A gradation of the 4h-accumulated MI was observed across the metastatic nodules (Fig. 3) . The highest rate of cellular proliferation was observed in the central tumour mass, with a significantly lower rate of mitosis at the periphery of the main tumour mass, and a further significant decrease in tumour-cell mitosis in the presence of lung tissue. These locational differences in the accumulated mitotic count were observed at all 3 sampling times after tumour-cell injection. Unfortunately, the sparsity of tumour-cell clusters made this kind of classification of tumour-cell counts in the lymph nodes impossible.
DISCUSSION
The present findings using the 4h-accumulated mitotic count as an indicator of cellular proliferation agree with the Bertalanffy and Lau (1962) that, following the latent period, no significant variation occurred in cellular proliferation during growth of solid tumours. The tumour grew at a steady rate after adaptation to a new host.
The higher rate of cellular proliferation in the lung and lymph-node metastases, when compared with primary tumours of either the same size or the same time after cell injection, supports the evidence of Kiseleva (1961) and that of SimpsonHerren, Sanford and Holmquist (1974) who showed that the cell cycle and S phase were shorter in Lewis lung carcinoma metastases than in the primary tumour. These findings are consistent with the greater drug sensitivity of lung metastases reported by Trope (1975) .
It may be suggested that this difference in cellular proliferation between metastases and primary tumour arises from selection of cells during or after implantation, resulting in a biochemically different phenotype in the metastases. This contention has some support from the work of Trope (1975) who demonstrated increased drug sensitivity in subcutaneous tumours derived from successive passages of the tumour as metastases.
Alternatively, it could be postulated that local factors in the host tissue specifially influence tumour proliferation. This may take the form of a more adequate blood supply and better nutrition in the metastases than in the primary tumour. The fact that necrotic areas were never observed in metastatic nodules supports this idea.
Our findings of a higher rate of cellular proliferation in the central mass of the metastases than in the peripheral areas may also be explained by regional differences in blood supply to the metastases. It may be that the established core of the tumour nodules is particularly well vascularised, compared with the periphery of the nodule. This rich vascularization may result in a higher rate of cellular proliferation near the capillaries (Tannock, 1970) as well as the removal of toxic metabolites, which may be one of the causes of necrosis and inhibition of cell division (Broyn, 1975b) .
However, there is increasing evidence of humoral factors, emanating from the host tissue, which influence tumour growth (Billingham and Silvers, 1971; Broyn, 1975a; Lowenstein and Penn, 1967; Van Scott and Reinertson, 1961) . Thus, the possibility that host lung tissue exerts some inhibitory influence on the development of metastases cannot be ignored. If this is the case, the gradation of this influence into the solid tumour mass indicates that this is not a cell-contact phenomenon, but rather supports the theory of diffusible humoral factor. In addition it may be tentatively suggested that differences in the effectiveness of host inhibitors may be involved in different site patterns of tumour growth.
